Quick Answer
CG Oncology, Inc. reported Operating Income of -$190.77 million for fiscal year 2025.
CG Oncology, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$190.77M | -66.4% |
| 2024 | -$114.67M | -106.8% |
| 2023 | -$55.45M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$51.13M | -80.7% | -4.9% |
| June 30, 2025 | -$48.74M | -88.5% | -15.5% |
| March 31, 2025 | -$42.20M | -87.8% | -49.2% |
| September 30, 2024 | -$28.30M | -101.5% | -9.4% |
| June 30, 2024 | -$25.85M | -109.7% | -15.1% |
| March 31, 2024 | -$22.47M | -131.1% | -60.0% |
| September 30, 2023 | -$14.04M | — | -13.9% |
| June 30, 2023 | -$12.33M | — | -26.8% |
- CG Oncology, Inc. showed a decrease of -66.4% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, CG Oncology, Inc.’s operating income has declined by 244.1% (from -$55.45 million to -$190.77 million).
- The most recent figure is from CG Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: